Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> ABBVIE Latest News

SEP 19, 2014 - TheStreet

A Must Read - Share

AbbVie (ABBV) Declares 42c Quarterly Dividend

NEW YORK (TheStreet) --aAbbVie declared a quarterly dividend of 42 cents a share Friday. Shares of the drug manufacturer were falling 0.3% to $59.26. The dividend is in line with the company's previous dividend. The new quarterly dividend is payable on Nov. 17 to all shareholders or record as of the close of business on Oct. 15. The ex-dividend date ...

Tags: AbbVie (ABBV) Declares 42c Quarterly Dividend,  Abbvie Latest News

SEP 15, 2014 - Zacks Investment Research

A Must Read - Share

Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog

Biogen Idec Inc. (BIIB) and partner AbbVie Inc. (ABBV) announced detailed positive results from the phase III study on Zinbryta.

Tags: Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog,  Abbvie Latest News

SEP 12, 2014 - Zacks Investment Research

A Must Read - Share

AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog

AbbVie Inc.'s (ABBV) Humira met the primary endpoint in a late-stage study conducted in patients suffering from moderate-to-severe hidradenitis suppurativa.

Tags: AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog,  Abbvie Latest News

SEP 11, 2014 - Benzinga

A Must Read - Share

AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy Of HUMIRA In Patients With Hidradenitis Suppurativa, A Chronic Inflammatory Skin Disease

Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 PIONEER I first Phase 3 trial to evaluate the investigational use of HUMIRA in patients with moderate-to-severe HS3 Results show HUMIRA meets primary endpoint3

Tags: AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy Of HUMIRA In Patients With Hidradenitis Suppurativa, A Chronic Inflammatory Skin Disease,  Abbvie Latest News

SEP 10, 2014 - Zacks Investment Research

A Must Read - Share